ZURA on XNAS, Health Care, Zura Bio Limited, job postings
Measures activity, not value. Not investment advice.
Shares fell 77% in one month while cash of $187.7M sits against an $89.6M market cap.
BadShort interest 8.8% of shares, up 21% from two weeks earlier
GoodInstitutional holders rose 26%, from 95 the quarter before to 120
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
Industry
Biological products, (no diagnostic substances) (Health Care)
expected around 24 Feb 2027 (an estimate: a year ago it reported on 25 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $25.8M.
31 Dec 2021RevenueNet incomeNet losstallest bar $34.0M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
–
-$25.8M
30 Jun 2026
–
-$26.3M
31 Mar 2026
–
-$24.2M
31 Dec 2025
–
-$17.2M
30 Sep 2025
–
-$18.0M
30 Jun 2025
–
-$16.0M
31 Mar 2025
–
-$17.4M
31 Dec 2024
–
-$13.6M
30 Sep 2024
–
-$20.7M
30 Jun 2024
–
-$10.3M
31 Mar 2024
–
-$7.7M
30 Sep 2023
–
-$8.3M
30 Jun 2023
–
-$34.0M
31 Mar 2023
–
-$9.6M
31 Dec 2022
–
$672K
30 Sep 2022
–
$458K
30 Jun 2022
–
$2.3M
31 Mar 2022
–
$148K
31 Dec 2021
–
$818K
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
–
–
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
–
+8.2%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$93.5M
-$65.1M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
-$1.12
-$0.65
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
–
–
70.4%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
–
–
-98.6%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
–
–
-47.8%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-65.4%
-58.2%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
–
-$53.5M
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$187.7M
$139.0M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$0
$0
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$187.7M (net cash)
-$139.0M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.0
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$1.84
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
21.6
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
–
8.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
–
6.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
0.50
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
–
No data for this company
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+26%
120 13F filers vs 95
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
72%
69.2M shares held by 13F filers (30 Sep 2026) of 96.3M outstanding (27 Oct 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
8.8%
8.5M shares sold short (30 Oct 2026) of 96.3M outstanding (27 Oct 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
1.8
8.5M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
+21%
7.0M shares sold short in the report before, 8.5M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
31%
31% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 41%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
–
We do not track this company's careers site yet.
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
We do not track this company's careers site yet.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
–
No data for this company
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
–
No data for this company
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
–
No data for this company
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
–
No data for this company
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
–
No data for this company
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
10
10 articles in the last 7 days; its usual week has 1.5 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
6.7×
10 articles in the last 7 days; its usual week has 1.5.
Price $0.93 on 20 Nov 2026, -75% over 12 months (12-month range $0.93 to $7.04)
Sharp change
8-K and other filings
Insider net buying (open market). Insiders bought a net $12.5M in the last 12 months (the 12 months before: $0).Capital spending per quarter. Capital spending $13K in the latest quarter, -73% on a year earlier.Institutional holders (13F filers). 120 13F filers reported holding it in the latest 13F quarter, +90% on a year earlier.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, revenue per quarter, federal obligations, lobbying spend, workers in warn layoff notices.
Quarter ended 31 Mar 2024: $7K; public on 10 May 2024
Quarter ended 30 Jun 2024: $10K; public on 14 Aug 2024
Quarter ended 30 Sep 2024: $13K; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $45K; public on 26 Mar 2025
Quarter ended 31 Mar 2025: $49K, +600% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $15K, +50% on a year earlier; public on 15 Aug 2025
Quarter ended 30 Sep 2025: $32K, +146% on a year earlier; public on 14 Nov 2025
Quarter ended 31 Dec 2025: $17K, -62% on a year earlier; public on 20 Mar 2026
Quarter ended 31 Mar 2026: $13K, -73% on a year earlier; public on 8 May 2026
Institutional holders (13F filers)
31 Mar 2023 report: 17; public on 15 May 2023
30 Jun 2023 report: 36; public on 14 Aug 2023
30 Sep 2023 report: 40; public on 14 Nov 2023
31 Dec 2023 report: 43; public on 14 Feb 2024
31 Mar 2024 report: 43; public on 15 May 2024
30 Jun 2024 report: 55; public on 14 Aug 2024
30 Sep 2024 report: 75; public on 14 Nov 2024
31 Dec 2024 report: 86; public on 14 Feb 2025
31 Mar 2025 report: 71; public on 15 May 2025
30 Jun 2025 report: 62; public on 14 Aug 2025
30 Sep 2025 report: 63; public on 14 Nov 2025
31 Dec 2025 report: 71; public on 17 Feb 2026
31 Mar 2026 report: 91; public on 15 May 2026
30 Jun 2026 report: 95; public on 14 Aug 2026
30 Sep 2026 report: 120; public on 16 Nov 2026
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market buying (USD, Form 4) at $12.5M (2 Mar 2026), higher than 100% of its own history.
had 6.2M shares sold short in the 15 Apr 2026 report, 2.4× the same report last year.
Same report last year: 2.6M; its normal report is 2.6M.
See the evidence
This period
6.2M (the 15 Apr 2026 report)
Normal report (median of 24 earlier)
2.6M
Typical spread (median absolute deviation)
512K
How far from its usual level
+4.7
Same report last year
2.6M
History used
1,111 days
the 15 Apr 2026 report24 earlier reportsnormal: 2.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 5.8M shares sold short in the 31 Mar 2026 report, 1.1× the same report last year.
Same report last year: 5.4M; its normal report is 2.6M.
See the evidence
This period
5.8M (the 31 Mar 2026 report)
Normal report (median of 24 earlier)
2.6M
Typical spread (median absolute deviation)
512K
How far from its usual level
+4.2
Same report last year
5.4M
History used
1,096 days
the 31 Mar 2026 report24 earlier reportsnormal: 2.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.9M shares sold short in the 31 Jan 2025 report, 15× the same report last year.
Same report last year: 329K; its normal report is 786K.
See the evidence
This period
4.9M (the 31 Jan 2025 report)
Normal report (median of 24 earlier)
786K
Typical spread (median absolute deviation)
456K
How far from its usual level
+6.1
Same report last year
329K
History used
672 days
the 31 Jan 2025 report24 earlier reportsnormal: 786K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 5.0M shares sold short in the 15 Jan 2025 report, 14× the same report last year.
Same report last year: 353K; its normal report is 716K.
See the evidence
This period
5.0M (the 15 Jan 2025 report)
Normal report (median of 24 earlier)
716K
Typical spread (median absolute deviation)
374K
How far from its usual level
+7.7
Same report last year
353K
History used
656 days
the 15 Jan 2025 report24 earlier reportsnormal: 716K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 5.0M shares sold short in the 31 Dec 2024 report, 11× the same report last year.
Same report last year: 437K; its normal report is 687K.
See the evidence
This period
5.0M (the 31 Dec 2024 report)
Normal report (median of 24 earlier)
687K
Typical spread (median absolute deviation)
331K
How far from its usual level
+8.7
Same report last year
437K
History used
641 days
the 31 Dec 2024 report24 earlier reportsnormal: 687K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 5.0M shares sold short in the 13 Dec 2024 report, 23× the same report last year.
Same report last year: 216K; its normal report is 653K.
See the evidence
This period
5.0M (the 13 Dec 2024 report)
Normal report (median of 24 earlier)
653K
Typical spread (median absolute deviation)
298K
How far from its usual level
+9.9
Same report last year
216K
History used
623 days
the 13 Dec 2024 report24 earlier reportsnormal: 653K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 5.2M shares sold short in the 29 Nov 2024 report, 30× the same report last year.
Same report last year: 173K; its normal report is 636K.
See the evidence
This period
5.2M (the 29 Nov 2024 report)
Normal report (median of 24 earlier)
636K
Typical spread (median absolute deviation)
280K
How far from its usual level
+10.9
Same report last year
173K
History used
609 days
the 29 Nov 2024 report24 earlier reportsnormal: 636K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 5.0M shares sold short in the 15 Nov 2024 report, 29× the same report last year.
Same report last year: 171K; its normal report is 599K.
See the evidence
This period
5.0M (the 15 Nov 2024 report)
Normal report (median of 24 earlier)
599K
Typical spread (median absolute deviation)
248K
How far from its usual level
+11.8
Same report last year
171K
History used
595 days
the 15 Nov 2024 report24 earlier reportsnormal: 599K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.8M shares sold short in the 31 Oct 2024 report, 3.8× the same report last year.
Same report last year: 462K; its normal report is 516K.
See the evidence
This period
1.8M (the 31 Oct 2024 report)
Normal report (median of 24 earlier)
516K
Typical spread (median absolute deviation)
187K
How far from its usual level
+4.5
Same report last year
462K
History used
580 days
the 31 Oct 2024 report24 earlier reportsnormal: 516K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.9M shares sold short in the 15 Oct 2024 report, 7.0× the same report last year.
Same report last year: 270K; its normal report is 449K.
See the evidence
This period
1.9M (the 15 Oct 2024 report)
Normal report (median of 24 earlier)
449K
Typical spread (median absolute deviation)
187K
How far from its usual level
+5.2
Same report last year
270K
History used
564 days
the 15 Oct 2024 report24 earlier reportsnormal: 449K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.9M shares sold short in the 30 Sep 2024 report, 6.5× the same report last year.
Same report last year: 285K; its normal report is 433K.
See the evidence
This period
1.9M (the 30 Sep 2024 report)
Normal report (median of 24 earlier)
433K
Typical spread (median absolute deviation)
179K
How far from its usual level
+5.4
Same report last year
285K
History used
549 days
the 30 Sep 2024 report24 earlier reportsnormal: 433K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.0M shares sold short in the 15 Aug 2024 report, 24× the same report last year.
Same report last year: 171K; its normal report is 371K.
See the evidence
This period
4.0M (the 15 Aug 2024 report)
Normal report (median of 24 earlier)
371K
Typical spread (median absolute deviation)
134K
How far from its usual level
+18.4
Same report last year
171K
History used
503 days
the 15 Aug 2024 report24 earlier reportsnormal: 371K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.4M shares sold short in the 31 Jul 2024 report, 19× the same report last year.
Same report last year: 185K; its normal report is 356K.
See the evidence
This period
3.4M (the 31 Jul 2024 report)
Normal report (median of 24 earlier)
356K
Typical spread (median absolute deviation)
123K
How far from its usual level
+16.9
Same report last year
185K
History used
488 days
the 31 Jul 2024 report24 earlier reportsnormal: 356K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.8M shares sold short in the 15 Jul 2024 report, 11× the same report last year.
Same report last year: 163K; its normal report is 341K.
See the evidence
This period
1.8M (the 15 Jul 2024 report)
Normal report (median of 24 earlier)
341K
Typical spread (median absolute deviation)
123K
How far from its usual level
+7.9
Same report last year
163K
History used
472 days
the 15 Jul 2024 report24 earlier reportsnormal: 341K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.
Showing the newest 40 of 63 entries; narrow the window or the kind of data to see older ones.
Not listed: 69 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001855644
Ticker
ZURA
Domain
zurabio.com
Hq location
CA|LA JOLLA|92037 (1 unverified)
Name
EX-21.1, JATT Acquisition Corp, JATT Merger Sub 2, a Cayman Islands exempted company, Z33 Bio Inc., a Delaware corporation and 5 more
SEC Form 13F institutional holdings135 data points31 Mar 2023 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)100 records15 Jun 2021 to 9 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)250 data points9 Mar 2021 to 27 Oct 2026
SEC Form 4 insider transactions11 records, 32 data points5 Jun 2023 to 2 Mar 2026
FINRA short interest (twice monthly)261 data points31 Mar 2023 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)1846 data points21 Mar 2023 to 20 Nov 2026